Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.610
+0.030 (1.90%)
Mar 13, 2026, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Employees
As of December 31, 2025, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees did not change compared to the previous year.
Employees
77
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$189,039
Profits / Employee
-$825,104
Market Cap
401.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 77 | 0 | - | 72 | 5 |
| Dec 31, 2024 | 77 | 2 | 2.67% | 70 | 7 |
| Dec 31, 2023 | 75 | -3 | -3.85% | 68 | 7 |
| Dec 31, 2022 | 78 | 17 | 27.87% | 70 | 8 |
| Dec 31, 2021 | 61 | 6 | 10.91% | 57 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Sutro Biopharma | 178 |
| Enanta Pharmaceuticals | 120 |
| Niagen Bioscience | 117 |
| Aura Biosciences | 109 |
| Armata Pharmaceuticals | 60 |
| PureTech Health | 56 |
| DiaMedica Therapeutics | 28 |
LCTX News
- 8 days ago - Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 16 days ago - Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Business Wire
- 2 months ago - Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
- 2 months ago - Lineage Cell Therapeutics Issues Letter to Stockholders - Business Wire
- 4 months ago - Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy - Seeking Alpha
- 4 months ago - Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire